News25/Ratings3
News · 26 weeks33+20%
2026-04-192026-10-11
Mix1590d
- SEC Filings5(33%)
- Insider4(27%)
- Earnings2(13%)
- Other2(13%)
- Leadership1(7%)
- Analyst1(7%)
Latest news
25 items- ANALYSTMaxim Group initiated coverage on Kyntra Bio with a new price targetMaxim Group initiated coverage of Kyntra Bio with a rating of Buy and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Kyntra Bio Inc.4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 3 filed by Kyntra Bio Inc.3 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SECSEC Form 8-K filed by Kyntra Bio Inc.8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- PRKyntra Bio Appoints Andrew E. Singer, MBA to its Board of DirectorsSAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service. "We are pleased to welcome Andy to the Board. His extensive experience across biotechnology finance, corporate development and public company operations will bring valuable perspective as Kyntra Bio continues to build momentum across its differentiated rare disease and oncology pipeline and
- INSIDERCEO Wettig Thane covered exercise/tax liability with 209 shares, decreasing direct ownership by 0.77% to 26,796 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERChief Financial Officer Delucia David covered exercise/tax liability with 22 shares, decreasing direct ownership by 0.50% to 4,355 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- PRKyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced that the company’s management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY. Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Tuesday, September 15 at 4:00 PM ET. A live webcast of the presentation will be available here. Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. The live audio webcast of the event will also be available to invest
- SECKyntra Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- PRKyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing ObligationCompany reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 millionCompany accelerated payment of $42.6 million upfront, bringing total payments made to date to $50 million, a full return of NQ Project Phoebus, L.P.’s invested capital, with up to $15 million of additional royalty-based payments to followRemaining payments, capped at $15 million, to be paid from 50% of the revenue received from Astellas in the Astellas territories excluding JapanPro forma for the upfront payment, cash, cash equivalents, investments, and accounts receivable of $53.1 million as of June 30, 2026 Cash runway now expected into the fourth quarter of 2027 SAN FRAN
- SECSEC Form 10-Q filed by Kyntra Bio Inc.10-Q - KYNTRA BIO, INC. (0000921299) (Filer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- PRKyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatePhase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring siderobla
- PRKyntra Bio to Report Second Quarter 2026 Financial ResultsSAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by
- ANALYSTOppenheimer initiated coverage on Kyntra Bio with a new price targetOppenheimer initiated coverage of Kyntra Bio with a rating of Outperform and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Director Ho Maykin4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Director Edwards Jeffrey L4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Director Kauffman Michael4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Director Schoeneck James A4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- PRKyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic SyndromesIn a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placeboSimilar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) diseasePivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA) SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced additional data
- INSIDERCEO Wettig Thane covered exercise/tax liability with 198 shares, decreasing direct ownership by 0.73% to 27,005 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERChief Financial Officer Delucia David covered exercise/tax liability with 52 shares, decreasing direct ownership by 1% to 4,377 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Other Events8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on Kyntra Bio with a new price targetRodman & Renshaw initiated coverage of Kyntra Bio with a rating of Buy and set a new price target of $30.00
KYNB FAQ
6 questionsWhere does KYNB stock trade?
Kyntra Bio Inc. (KYNB) is listed on NASDAQ.What sector and industry is KYNB in?
Kyntra Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kyntra Bio Inc. go public?
Kyntra Bio Inc. (KYNB) completed its IPO in 2014.What are analysts saying about KYNB?
Kyntra Bio Inc. has had 3 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $3500.00 price target on 2026-10-13. Recent price targets range from $3000.00 to $3500.00.What companies are similar to KYNB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KYNB side-by-side with any of them on Quantisnow.How can I track KYNB on Quantisnow?
Quantisnow aggregates Kyntra Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYNB to receive live email and push alerts on every new disclosure.